Loading...
•
Jun 30, 2025
Mimedx Q2 2025 Earnings Report
Mimedx reported record second quarter 2025 operating and financial results, with net sales growing 13% year-over-year.
Key Takeaways
Mimedx achieved its highest quarterly net sales in company history, reaching $99 million, driven by double-digit growth in both Wound and Surgical product categories. The company also reported a record Adjusted EBITDA of $24 million, reflecting strong operational efficiency and expense discipline. GAAP net income and diluted EPS were $10 million and $0.06, respectively.
Net sales for Q2 2025 reached a record $99 million, a 13% increase year-over-year.
Adjusted EBITDA for the quarter was $24 million, representing 25% of net sales.
Both Wound and Surgical product categories demonstrated strong double-digit growth, contributing to the overall sales increase.
The company raised its 2025 net sales growth expectations to low double-digits for the full year.
Revenue by Segment
Forward Guidance
Mimedx has raised its 2025 net sales growth expectations to low double-digits and continues to expect adjusted EBITDA margin to be above 20% for the full year and longer-term.
Positive Outlook
- Expects net sales growth in the low double-digits for the full year 2025.
- Anticipates 2025 Adjusted EBITDA margin to be above 20% on a full year basis.
- Longer-term, the company expects annual net sales growth in the low double-digits.
- Longer-term, the company expects adjusted EBITDA margin above 20%.
- Welcomes and supports CMS proposal to overhaul reimbursement of skin substitutes, expecting it to drive cost savings and prioritize patient care.
Challenges Ahead
- Future sales are uncertain and affected by competition.
- Access to customers and patient access to healthcare providers can impact sales.
- The reimbursement environment poses a risk to future sales.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...